Aulos Bioscience

Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics. Their initial clinical candidate, AU-007, stands apart from existing IL-2 therapeutics by introducing a novel approach that addresses a significant medical challenge of the present era: the eradication of cancer. Through harnessing the anti-cancer potential of interleukin-2, they are breaking down barriers in the field of immuno-oncology. Their distinctive immunotherapy, computationally designed to precisely guide the immune system in attacking tumor cells, is poised to make a substantial impact.